The Founder's Father Was a Doctor in Colombia Who Died at 58 from a Drug Interaction AI Could Have Caught. a16z Just Led the Series A.

When a16z announced its investment in Telepatia, the firm's tweet didn't open with TAM or ARR. It opened with this: "Nicolás's father was a physician in Colombia who died at 58 from a drug interaction AI could have flagged in seconds." Telepatia raised $33 million in a Series A led by Andreessen Horowitz, with Palantir CTO Shyam Sankar, Rappi founder Simón Borrero, and Nubank founder David Vélez among the participants. The personal framing is unusual — top-tier VCs rarely lead funding announcements with founder grief. It is also precise: it tells you exactly what the product is and why it will be used.

Since launching in July 2025, Telepatia has deployed its AI-native clinical platform across 25+ hospital systems in Brazil, Colombia, and Mexico. The platform combines AI documentation, clinical decision support, and specialized AI agents — functioning as AI doctors, nurses, and auditors — trained on clinical guidelines, peer-reviewed literature, and local institutional protocols. Protocol adherence across deployed hospitals has risen from 84% to 99%. Physicians recover 1.7 hours per day. The platform has prevented 60,000 medical errors in real time. Total patients reached: 14 million, in under one year of deployment.

The investment thesis is structural, not operational. Latin American healthcare operates with deep physician shortages, fragmented information systems, and clinical guideline adherence rates that lag those in developed markets. The constraint cannot be solved by training more doctors — the timeline is a decade per cohort. An AI clinical platform that embeds into existing hospital workflows, adapts to local protocols, and improves adherence without changing staffing levels is addressing a structural gap, not a workflow inefficiency. Structural constraints produce TAMs that do not compress when addressed.

The cap table is as informative as the metrics. Simón Borrero built Rappi from Colombia into the region's largest on-demand logistics platform, navigating regulatory environments across nine countries. David Vélez built Nubank into the world's largest digital bank by users, beginning in Brazil with a market that global banks had written off. These are not tourism investors taking a position in an emerging market they don't understand. They are founders who built distribution in the exact geographies Telepatia is entering — and they chose to invest at the Series A, not wait for a later stage.

Telepatia's goal is to reach half of the region's 1.9 million doctors by end of 2027 — roughly 950,000 physicians across Brazil, Mexico, Colombia, Chile, and Argentina. At that penetration, the company becomes the largest clinical data asset in Latin America: trained on real-world patient interactions, local treatment protocols, and multi-country outcome data that no global competitor can replicate without years of regional presence. That is the asset a16z is acquiring a position in. Not the current revenue. Not even the current product. The data layer that compounds with every deployed physician — in a market where the problem is both large and personal enough that the founder didn't need to be convinced it was worth solving.